AffaMed Technologies, a joint venture established between AffaMed Therapeutics and SIFI S.p.A., have announced that the Taiwan Food and Drug Administration (TFDA) has approved its MINI WELL, MINI WELL PROXA, MINI WELL TORIC and MINI 4 Ready intraocular lens (IOL) surgical implants for use in cataract treatment in Taiwan.

MINI WELL, MINI WELL PROXA and MINI WELL TORIC are presbyopia-correcting IOLs that can provide progressive extended depth-of-focus (EDOF) vision correction to patients after cataract surgery, with MINI WELL TORIC able to correct up to 3.0D of corneal astigmatism.

These surgical implants represent the most advanced solutions for cataract refractive surgery, allowing correction of myopia / hyperopia, presbyopia and corneal astigmatism resulting in spectacle-free uninterrupted high-quality vision at all distances and in all lighting conditions. MINI 4 Ready is an aspheric mono-focal IOL.

Dr Dayao ZHAO, CEO of AffaMed Therapeutics commented, "These regulatory approvals mark important milestones for our company and illustrate Affamed's dedication to develop and commercialise high-quality and differentiated treatment solutions in Greater China. We look forward to a successful launch of our advanced IOL solutions in Taiwan and bringing their significant benefits in vision correction to patients in the near future."